Payment overview · 2025
General Payments
$561.53
35 reported records · 16 companies
Healthcare provider profile · identity verified
Ghayth Mahmoud Hammad, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MORGANTOWN, KY · NPI 1184719874
Verified facts
What the public records show
CMS Open Payments records show Ghayth Mahmoud Hammad, MD received $561.53 in general payments during 2025 across 35 reported records.
Amgen Inc. accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Trelegy Ellipta, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 545 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $163.21 | 29.1% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $108.05 | 19.2% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $39.93 | 7.1% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $36.83 | 6.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.52 | 4.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.44 | 4.0% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $22.28 | 4.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.85 | 3.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.23 | 3.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.27 | 3.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.91 | 2.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.83 | 2.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.36 | 2.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.77 | 2.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.71 | 2.4% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $8.34 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $561.53 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $163.21 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $77.80 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $42.49 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $39.93 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $36.83 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.31 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.52 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $8.34 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $3.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 545 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 83 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 80 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
55 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
80 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
545 | 84 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 965 | 270 |
| Levothyroxine Sodium | Levothyroxine Sodium | 808 | 163 |
| Eliquis | Apixaban | 545 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 543 | 173 |
| Amlodipine Besylate | Amlodipine Besylate | 487 | 159 |
| Lisinopril | Lisinopril | 437 | 158 |
| Furosemide | Furosemide | 387 | 103 |
| Carvedilol | Carvedilol | 353 | 116 |
| Tamsulosin Hcl | Tamsulosin Hcl | 348 | 96 |
| Losartan Potassium | Losartan Potassium | 331 | 130 |
| Metoprolol Tartrate | Metoprolol Tartrate | 329 | 93 |
| Omeprazole | Omeprazole | 327 | 132 |
| Sertraline Hcl | Sertraline Hcl | 293 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 292 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 267 | 131 |
| Gabapentin | Gabapentin | 257 | 80 |
| Clopidogrel | Clopidogrel Bisulfate | 250 | 73 |
| Trazodone Hcl | Trazodone Hcl | 219 | 48 |
| Metformin Hcl | Metformin Hcl | 198 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 86 |
| Citalopram Hbr | Citalopram Hydrobromide | 186 | 53 |
| Montelukast Sodium | Montelukast Sodium | 185 | 69 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 163 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 161 | 35 |
| Donepezil Hcl | Donepezil Hcl | 160 | 29 |
| Memantine Hcl | Memantine Hcl | 159 | 23 |
| Januvia | Sitagliptin Phosphate | 153 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 151 | 55 |
| Levetiracetam | Levetiracetam | 150 | 19 |
| Potassium Chloride | Potassium Chloride | 150 | 45 |
| Divalproex Sodium | Divalproex Sodium | 146 | 14 |
| Glimepiride | Glimepiride | 138 | 48 |
| Warfarin Sodium | Warfarin Sodium | 136 | suppressed |
| Meloxicam | Meloxicam | 135 | 52 |
| Buspirone Hcl | Buspirone Hcl | 127 | 37 |
| Alendronate Sodium | Alendronate Sodium | 126 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 126 | 71 |
| Finasteride | Finasteride | 122 | 34 |
| Ondansetron Odt | Ondansetron | 118 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 113 | 26 |
| Metformin Hcl Er | Metformin Hcl | 112 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 45 |
| Ropinirole Hcl | Ropinirole Hcl | 108 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 49 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 104 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 102 | 31 |
| Ozempic | Semaglutide | 101 | 33 |
| Jardiance | Empagliflozin | 99 | 18 |
| Olanzapine | Olanzapine | 88 | 13 |
| Azithromycin | Azithromycin | 87 | 60 |
| Allopurinol | Allopurinol | 86 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 22 |
| Mirtazapine | Mirtazapine | 84 | 14 |
| Farxiga | Dapagliflozin Propanediol | 83 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 82 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 21 |
| Mounjaro | Tirzepatide | 79 | 20 |
| Sucralfate | Sucralfate | 78 | 13 |
| Prednisone | Prednisone | 73 | 42 |
| Famotidine | Famotidine | 72 | 27 |
| Brilinta | Ticagrelor | 70 | 16 |
| Clonidine Hcl | Clonidine Hcl | 70 | 25 |
| Novolog Flexpen | Insulin Aspart | 69 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 68 | 11 |
| Bumetanide | Bumetanide | 66 | 20 |
| Spironolactone | Spironolactone | 62 | 20 |
| Tradjenta | Linagliptin | 61 | suppressed |
| Nitroglycerin | Nitroglycerin | 58 | 26 |
| Lactulose | Lactulose | 57 | suppressed |
| Lorazepam | Lorazepam | 57 | suppressed |
| Risperidone | Risperidone | 57 | suppressed |
| Alprazolam | Alprazolam | 56 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 22 |
| Linzess | Linaclotide | 55 | 20 |
| Digoxin | Digoxin | 54 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 23 |
| Levemir Flexpen | Insulin Detemir | 52 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 51 | suppressed |
| Topiramate | Topiramate | 49 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 26 |
| Simvastatin | Simvastatin | 48 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 33 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 45 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 45 | suppressed |
| Nystatin | Nystatin | 44 | 24 |
| Synthroid | Levothyroxine Sodium | 42 | 18 |
| Enoxaparin Sodium | Enoxaparin Sodium | 41 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 41 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 41 | 16 |
| Xarelto | Rivaroxaban | 41 | 13 |
| Bupropion Xl | Bupropion Hcl | 40 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 20 |
| Celecoxib | Celecoxib | 39 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Glipizide | Glipizide | 36 | 11 |
| Ibuprofen | Ibuprofen | 36 | 18 |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 36 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 31 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 30 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 15 |
| Methocarbamol | Methocarbamol | 30 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | 17 |
| Morphine Sulfate | Morphine Sulfate | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 23 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | 11 |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 27 | 12 |
| Movantik | Naloxegol Oxalate | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | 15 |
| Cefuroxime | Cefuroxime Axetil | 26 | 21 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Xifaxan | Rifaximin | 26 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Invokana | Canagliflozin | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | 14 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Tresiba | Insulin Degludec | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | 14 |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Latuda | Lurasidone Hcl | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | 12 |
| Insulin Aspart Flexpen | Insulin Aspart | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 20 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 20 | suppressed |
| Repatha Syringe | Evolocumab | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 19 | suppressed |
| Budesonide | Budesonide | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Famciclovir | Famciclovir | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Dofetilide | Dofetilide | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 15 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | 12 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Yupelri | Revefenacin | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $561.53 · 35 records | Amgen Inc. | ABRYSVO, AREXVY, Auvelity, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENDURANT IIS, FARXIGA, Hillrom - Vest System Model 105 Home Care, ImmunoCAP, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, REXULTI, RHYTHM EXPRESS, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, XIFAXAN, ZAVZPRET, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error